Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-12-09 pm EST
175.74 USD   -0.82%
11:52aIN BRIEF: Johnson & Johnson submits licence application to FDA
AN
10:05aJohnson & Johnson's Janssen Unit Files Biologics License Application With FDA for Experimental Multiple Myeloma Drug
MT
09:23aJohnson & Johnson : Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: January 2019 2020 2021 2022 2023 2024
Capitalization1 384 174414 310450 358463 286--
Enterprise Value (EV)1 392 583424 391452 501452 481443 149432 239
P/E ratio 25,9x28,6x21,9x22,3x20,4x19,6x
Yield 2,57%2,53%2,45%2,47%2,60%2,73%
Capitalization / Revenue 4,68x5,02x4,80x4,87x4,75x4,64x
EV / Revenue 4,78x5,14x4,83x4,76x4,54x4,33x
EV / EBITDA 14,0x15,6x12,4x13,9x12,9x12,2x
Enterprise Value (EV) / FCF 19,7x21,0x22,9x19,7x16,7x16,1x
FCF Yield 5,07%4,76%4,37%5,07%6,00%6,21%
Price to Book 6,46x9,53x6,08x6,04x5,58x5,12x
Nbr of stocks (in thousands) 2 631 8722 632 5432 632 5972 614 484--
Reference price (USD) 146157171177177177
Announcement Date 01/22/202001/26/202101/25/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: January 2019 2020 2021 2022 2023 2024
Net sales1 82 05982 58493 77595 03997 53899 882
EBITDA1 27 97927 14536 63432 49434 26235 518
Operating profit (EBIT)1 25 59324 57429 24429 60730 89632 161
Operating Margin 31,2%29,8%31,2%31,2%31,7%32,2%
Pre-Tax Profit (EBT)1 17 32816 49722 77625 75926 76627 842
Net income1 15 11914 71420 87820 67722 44023 719
Net margin 18,4%17,8%22,3%21,8%23,0%23,7%
EPS2 5,635,517,817,948,709,04
Dividend per Share2 3,753,984,194,374,614,84
Announcement Date 01/22/202001/26/202101/25/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: January 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 23 42624 02023 79123 92423 77624 381
EBITDA1 9 3059 0119 2997 4908 7668 924
Operating profit (EBIT)1 7 5367 2677 6146 7237 5747 641
Operating Margin 32,2%30,3%32,0%28,1%31,9%31,3%
Pre-Tax Profit (EBT)1 5 8625 8405 8226 030--
Net income1 --4 4584 6436 1825 471
Net margin --18,7%19,4%26,0%22,4%
EPS2 1,931,801,681,872,062,10
Dividend per Share ------
Announcement Date 04/19/202207/19/202210/18/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: January 2019 2020 2021 2022 2023 2024
Net Debt1 8 40910 0812 143---
Net Cash position1 ---10 80620 13731 047
Leverage (Debt / EBITDA) 0,30x0,37x0,06x-0,33x-0,59x-0,87x
Free Cash Flow1 19 91820 18919 75822 92526 59826 822
ROE (Net Profit / Equities) 39,1%34,9%38,2%35,4%34,6%32,9%
Shareholders' equity1 38 66442 13454 71658 36864 79972 072
ROA (Net Profit / Asset) 15,0%12,9%14,7%13,3%13,8%14,2%
Assets1 100 753114 174142 233155 024162 822166 603
Book Value Per Share2 22,616,528,229,331,734,6
Cash Flow per Share2 8,728,818,7510,811,812,6
Capex1 3 4983 3473 6523 7293 7723 871
Capex / Sales 4,26%4,05%3,89%3,92%3,87%3,88%
Announcement Date 01/22/202001/26/202101/25/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 463 286 495 160
Net sales (USD) 93 775 000 000
Number of employees 141 700
Sales / Employee (USD) 661 785
Free-Float 83,8%
Free-Float capitalization (USD) 388 178 186 095
Avg. Exchange 20 sessions (USD) 1 214 921 831
Average Daily Capital Traded 0,26%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA